Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
Atossa Therapeutics (NASDAQ:ATOS) will host a live investor webinar and Q&A session on May 22, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Dr. Steven Quay discussing the company's lead clinical candidate, (Z)-endoxifen, a next-generation SERM targeting metastatic breast cancer. The presentation will cover multiple ongoing Phase 2 studies showing strong clinical activity, improved tolerability, and favorable safety profiles. Investors will learn about recent progress, upcoming milestones, and how Atossa's differentiated science and capital-efficient model aim to create clinical impact and shareholder value.
Atossa Therapeutics (NASDAQ:ATOS) terrà un webinar dal vivo per investitori con una sessione di domande e risposte il 22 maggio 2025 alle 16:15 ET. L'evento, organizzato da RedChip Companies, vedrà la partecipazione del CEO Dr. Steven Quay, che parlerà del principale candidato clinico dell'azienda, (Z)-endoxifen, un SERM di nuova generazione mirato al trattamento del cancro al seno metastatico. La presentazione illustrerà diversi studi di Fase 2 in corso che evidenziano una forte attività clinica, una migliore tollerabilità e profili di sicurezza favorevoli. Gli investitori potranno conoscere i progressi recenti, le prossime tappe e come la scienza differenziata di Atossa e il modello efficiente in termini di capitale puntino a generare impatto clinico e valore per gli azionisti.
Atossa Therapeutics (NASDAQ:ATOS) realizará un seminario web en vivo para inversores con una sesión de preguntas y respuestas el 22 de mayo de 2025 a las 4:15 p.m. ET. El evento, organizado por RedChip Companies, contará con la participación del CEO, el Dr. Steven Quay, quien hablará sobre el principal candidato clínico de la compañía, (Z)-endoxifen, un SERM de nueva generación dirigido al cáncer de mama metastásico. La presentación cubrirá varios estudios de Fase 2 en curso que muestran una fuerte actividad clínica, mejor tolerabilidad y perfiles de seguridad favorables. Los inversores conocerán los avances recientes, los próximos hitos y cómo la ciencia diferenciada de Atossa y su modelo eficiente en capital buscan generar un impacto clínico y valor para los accionistas.
Atossa Therapeutics (NASDAQ:ATOS)는 2025년 5월 22일 오후 4시 15분 ET에 투자자를 위한 라이브 웨비나 및 질의응답 세션을 개최합니다. RedChip Companies가 주최하는 이번 행사에는 CEO Dr. Steven Quay가 참석하여 회사의 주요 임상 후보물질인 (Z)-엔도키센에 대해 설명할 예정이며, 이는 전이성 유방암을 표적으로 하는 차세대 SERM입니다. 발표에서는 강력한 임상 활동, 개선된 내약성 및 우수한 안전성 프로필을 보여주는 여러 진행 중인 2상 연구들이 다뤄질 것입니다. 투자자들은 최근 진행 상황, 다가오는 이정표, 그리고 Atossa의 차별화된 과학 및 자본 효율적 모델이 어떻게 임상적 영향과 주주 가치를 창출하는지에 대해 알게 될 것입니다.
Atossa Therapeutics (NASDAQ:ATOS) organisera un webinaire en direct pour les investisseurs avec une séance de questions-réponses le 22 mai 2025 à 16h15 ET. L'événement, animé par RedChip Companies, mettra en vedette le PDG Dr Steven Quay qui présentera le principal candidat clinique de la société, le (Z)-endoxifène, un SERM de nouvelle génération ciblant le cancer du sein métastatique. La présentation couvrira plusieurs études de phase 2 en cours montrant une forte activité clinique, une meilleure tolérance et des profils de sécurité favorables. Les investisseurs découvriront les progrès récents, les prochaines étapes et comment la science différenciée d’Atossa et son modèle capital-efficient visent à créer un impact clinique et de la valeur pour les actionnaires.
Atossa Therapeutics (NASDAQ:ATOS) veranstaltet am 22. Mai 2025 um 16:15 Uhr ET ein Live-Webinar für Investoren mit einer Fragerunde. Die Veranstaltung, organisiert von RedChip Companies, wird vom CEO Dr. Steven Quay geleitet, der den führenden klinischen Kandidaten des Unternehmens, (Z)-Endoxifen, ein SERM der nächsten Generation zur Behandlung von metastasiertem Brustkrebs, vorstellt. Die Präsentation umfasst mehrere laufende Phase-2-Studien, die eine starke klinische Wirksamkeit, verbesserte Verträglichkeit und günstige Sicherheitsprofile zeigen. Investoren erfahren mehr über die jüngsten Fortschritte, bevorstehende Meilensteine und wie Atossas differenzierte Wissenschaft und kapital-effizientes Modell darauf abzielen, klinische Wirkung und Aktionärswert zu schaffen.
- None.
- None.
SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Dr. Steven Quay, CEO of Atossa Therapeutics.
Attendees will gain insight into Atossa's strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen - a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company's differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value.
A live question and answer session will follow the presentation.
To register for the free webinar, please visit: https://www.redchip.com/webinar/atos/86715412603
Questions can be pre-submitted to ATOS@redchip.com or online during the live event.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the potential indications that the Company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval, benefits of the Company's strategy of pursuing a metastatic indication for (Z)-endoxifen, the expected design and enrollment of trials and timing of data and related publications, and the potential market and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: our ability to obtain patent coverage for our product candidates; macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance or maintain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
ATOS@redchip.com
SOURCE: Atossa Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Atossa Therapeutics (ATOS) hosting its investor webinar?
What will be discussed in ATOS's May 2025 investor webinar?
Who will be presenting at the Atossa Therapeutics webinar?
How can investors participate in ATOS's May 2025 webinar?
